Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Collplant Biotechnologies (CLGN) · oqro.io/stocks/CLGN · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Collplant Biotechnologies insider trading
Have Collplant Biotechnologies insiders bought shares recently?
No open-market purchase by an insider of Collplant Biotechnologies is on record in SEC filings since 2006.
Who is selling Collplant Biotechnologies stock?
No open-market sale by an insider of Collplant Biotechnologies (CLGN) was filed with the SEC in the last 90 days.
Do members of Congress trade CLGN?
No trade in Collplant Biotechnologies (CLGN) was disclosed by a member of Congress in the last 12 months.
When does Collplant Biotechnologies report its next results?
Collplant Biotechnologies's next results are expected on Nov 24, 2026. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
CLGN price and disclosed activity
−75.4% (−$14.26) from Nov 12, 2025 to Nov 12, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $18.90 on Nov 12, 2025 to $4.64 on Nov 12, 2026 (−75.4%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$0$10$15$20$25$4.64
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Orthopedic, Prosthetic & Surgical Appliances & Supplies company based in Rehovot, Israel. Foreign private issuer: reports on Form 20-F or 40-F.
Full company description
Orthopedic, Prosthetic & Surgical Appliances & Supplies company based in Rehovot, Israel. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
−75.5%
S&P 500 +10.8% over the same dates
Market value
–
Foreign issuers do not report a share count in the SEC data we read
S&P 500 +10.8% over the same dates. Prices adjusted for splits and dividends.
Short interest: 36K shares sold short, −32.5% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
A major shareholder of Collplant Biotechnologies told the SEC about a plan to sell $59K of Collplant Biotechnologies shares around Oct 27, 2026. The shares were not acquired as compensation. That is 0.1% of all Collplant Biotechnologies shares.
A Schedule 13D means the holder owns more than 5% and keeps the option to push for changes: board seats, a sale, buybacks. It must be filed within 5 business days.
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
When insiders usually buy
Last results
—
Next results, expected
Nov 24, 2026
Purchases after results
Not enough history
From Collplant Biotechnologies's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Collplant Biotechnologies's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Where the revenue comes from
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Mar 26, 2026. Read the filing
By product or service
Revenues from licensing agreement$2M84%
No figure for the year before
Revenues from the Sales of Goods$371K16%
−28% on the year before ($515K)
Total revenue$2.37M+360%
By region
United States$2.18M92%
+350% on the year before ($484K)
Europe and Other$98K4.1%
No figure for the year before
Canada$96K4.0%
No figure for the year before
Israel$1K0.0%
−97% on the year before ($31K)
Total revenue$2.37M+360%
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 5,000 words.
From “Overview”, in the company's words
We are a regenerative and aesthetic medicine company focused on medical aesthetics and 3D bioprinting of tissues and organs. Our products are based on our recombinant human collagen (rhCollagen) that is produced with our proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. We are in collaboration with AbbVie under the AbbVie Development Agreement, pursuant to which dermal and soft tissue filler products are being developed by AbbVie for commercialization in the medical aesthetics market, using our rhCollagen technology and AbbVie’s technology.
What the section covers (24 headings)
Overview
Financial Operations Overview
Revenues
Cost of Revenues
Operating Expenses
Research and Development Expenses
General, Administrative, and Marketing Expenses
Financial Income/Financial Expenses
Taxes on Income
A. Operating Results
Financial Income (Expenses), Net
Recent Accounting Pronouncements
Source: SEC EDGAR, Form 20-F filed Mar 26, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
B. Liquidity and Capital Resources
Cash Flows
And 10 more headings in the filing.
Off-exchange trading: 47.8% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (7.6% on ATS, 40.2% with other brokers), above its 6-week average of 44.0%. Weeks of Sep 21 to Oct 16, 2026.
Week of Sep 7ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: IBKR ATS (22.5%), UBS ATS (17.0%), SIGMA X2 (6.0%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Funds and stakes. Ami Sagy disclosed a 5.7% stake in CLGN (filed Oct 8, 2026). Ami Sagy now owns 5.7% of CLGN as a passive investor (filed Oct 8, 2026). (Collplant Biotechnologies on OQRO)
Contracts, lobbying and filings. FINRA short interest for CLGN on the settlement date of Oct 30, 2026 was 35,612 shares (-32.47% on the previous report), about 1.03 days of average volume.
Company reports, price and press. Press coverage listed by Finnhub: "CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol 'OPHI'" (Yahoo, Nov 12, 2026). Press coverage listed by Finnhub: "CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light" (Yahoo, Nov 4, 2026).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Funds and stakes
Ami Sagy disclosed a 5.7% stake in CLGN (filed Oct 8, 2026).
Ami Sagy now owns 5.7% of CLGN as a passive investor (filed Oct 8, 2026).
Contracts, lobbying and filings
FINRA short interest for CLGN on the settlement date of Oct 30, 2026 was 35,612 shares (-32.47% on the previous report), about 1.03 days of average volume.
Company reports, price and press
Press coverage listed by Finnhub: "CollPlant to Begin Trading on Nasdaq Under New Ticker Symbol 'OPHI'" (Yahoo, Nov 12, 2026).
Press coverage listed by Finnhub: "CollPlant Announces Proposed Name Change to OptiPhi Computing Reflecting Expansion to Computing with Light" (Yahoo, Nov 4, 2026).
Press coverage listed by Finnhub: "COLLPLANT ANNOUNCES A $3.7 MILLION PRIVATE PLACEMENT" (Yahoo, Oct 9, 2026).
CLGN closed at $4.64 on Nov 12, 2026, the last session on or before the end of the period.
From Oct 13, 2026 to Nov 12, 2026, the close moved from $3.91 to $4.64, a change of +18.7%.
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Headlines are listed as published by the outlets; OQRO has not checked them and does not summarise articles.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Latest annual report filed Mar 26, 2026, compared with the one filed Mar 26, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
Management has concluded that there is substantial doubt about our ability to continue as a going concern, and the report of our independent registered public accounting firm contains an explanatory paragraph as to our ability to continue as a going concern, which could prevent us from obtaining new financing on reasonable terms or at all.
Inadequate funding for the FDA and other government agencies and/or potentially shifting priorities under the current administration could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, cleared, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
Even if one or more of our products are approved by the FDA, we may fail to obtain an adequate level of reimbursement for our products by third party payors, such that there may be no commercially viable markets for our products, or the markets may be much smaller than expected.
No longer listed (2 headings from the year before)
Our business may be adversely affected if there is a resurgence of the COVID-19 pandemic.
If a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax consequences.
Source: SEC EDGAR, Form 20-F filed Mar 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.